FATE
FATE THERAPEUTICS INCPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- May 11 ▲ Fate Therapeutics presented clinical and preclinical data at ASGCT 2…
- May 20 ▼ 2 insiders sell $102.6K at $1.88
- Jun 1 ▲ Fate Therapeutics presented early Phase 1 data for FT836, an off-the…
- Jun 1 FDA: Fate Therapeutics Showcases Clinical Data for FT836 at the…
- Jun 2 Activist stake: Fate Therapeutics Reports New Employee Inducement Awards U…
- Aug 4 ▼ 2 insiders sell $203.5K at $2.46
- Aug 14 FDA: Fate Therapeutics Initiates Potentially Registrational REC…
- Nov 3 ▼ 1 insider sell $13.5K at $2.05
Signal stack
Where each data set points today.
- InsidersBEARISH
3 insiders sold $319.6K.
- InstitutionsBEARISH
Q3 2026: 13 added (0 new), 21 trimmed or exited.
- AnalystsBULLISH
11 of 18 rate it Buy or better. Every target is above the price.
- EstimatesRISING
Current-quarter EPS estimate −$0.276 → −$0.241 over 90 days. 1 up, 0 down in 30 days.
- Short sellersSTEADY
Short interest −6.1% to 9.97M shares. 8.3 days to cover, ≈8.2% of shares.
- TrendDOWNTREND
46% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | DOUBLED | $5.6M |
| Qube Research & Technologies Ltd | DOUBLED | $3.9M |
| Assenagon Asset Management S.A. | DOUBLED | $3.1M |
| Connor, Clark & Lunn Investment Management Ltd. | ADD | $1.7M |
| DIMENSIONAL FUND ADVISORS LP | ADD | $1.2M |
| UBS Group AG | TRIM | $406.3K |
| AMERICAN CENTURY COMPANIES INC | ADD | $364.3K |
| Jefferies Financial Group Inc. | ADD | $226.6K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
18 analystsPrice is below the lowest target. Median implies +514%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 6, 2026 | Wells Fargo MAINTAIN | Equal-Weight |
| Oct 27, 2026 | Wedbush REITERATE | Outperform |
| Aug 14, 2026 | Piper Sandler REITERATE | Overweight |
| Aug 14, 2026 | Wells Fargo MAINTAIN | Equal-Weight |
| Aug 14, 2026 | Wedbush REITERATE | Outperform |
| Jun 8, 2026 | HC Wainwright & Co. REITERATE | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Adawi Kamal Chief Financial Officer Nov 3, 2026 | SELL | $13.5K |
Valamehr Bahram President and CEO Aug 4, 2026 | SELL | $108.1K |
TAHL CINDY See Remarks Aug 4, 2026 | SELL | $95.4K |
Redmile Group, LLC Director Jun 12, 2026 | AWARD | 87,900 sh |
Lee Michael Stewart Director Jun 12, 2026 | AWARD | 87,900 sh |
Hamill Laura Director Jun 12, 2026 | AWARD | 175,800 sh |
ABERNETHY MATT Director Jun 12, 2026 | AWARD | 87,900 sh |
RASTETTER WILLIAM H Director Jun 12, 2026 | AWARD | 87,900 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.24 | -$0.27–-$0.20 | +10.6% | $154.3K |
| Next Q | -$0.26 | -$0.33–-$0.23 | +5.2% | $350.0K |
| Current FY | -$0.97 | -$1.02–-$0.85 | +4.9% | $3.5M |
| Next FY | -$0.97 | -$1.30–-$0.69 | -0.1% | $3.1M |
Short side
FINRA· Oct 30, 2026SecBot reports
18 filings · 3 press releases · 1 bullish · 6 bearish · 11 neutral- BEARISH EFFECTNov 13, 2026
Fate Therapeutics' universal shelf registration (S-3, File No. 333-299862) became effective on…
Monitor for takedowns under the ATM facility or any follow-on offering, which would crystallize dilution. The company's cash runway and pipeline milestones will determine the pace of capital…
- BEARISH 424B5Nov 12, 2026
Fate Therapeutics filed a 424B5 prospectus supplement establishing a new $100M at-the-market (ATM)…
Monitor quarterly disclosures of shares sold under the ATM to gauge actual dilution. The company's cash runway extends to mid-2028 per Q3 2026 guidance, but the ATM signals ongoing capital needs for…
- NEUTRAL SC 13D/ANov 9, 2026
Redmile Group filed Amendment No. 11 to its Schedule 13D solely to add Redmile Capital Offshore II…
This is a routine administrative amendment with no change in position or intent. Monitor for any future 13D amendments that signal a change in strategy, such as increasing the blocker limit or…
- NEUTRAL S-3Nov 5, 2026
Fate Therapeutics filed a new universal shelf registration statement (S-3) to replace its expiring…
Monitor ATM sales disclosures in future 10-Qs to gauge pace of equity issuance. The shelf provides flexibility but the company's cash burn rate and clinical trial milestones will determine actual…
All FATE filing & press-release reports (21)
- EFFECT reportNov 13, 2026
- 424B5 reportNov 12, 2026
- SC 13D/A reportNov 9, 2026
- S-3 reportNov 5, 2026
- 424B5 reportNov 5, 2026
- 8-K reportNov 5, 2026
- 8-K reportNov 5, 2026
- PRESS-RELEASE reportNov 5, 2026
- INST-CLUSTER reportNov 4, 2026
- 144 reportNov 3, 2026
- PRESS-RELEASE reportOct 1, 2026
- 8-K reportSep 28, 2026
- PRESS-RELEASE reportAug 14, 2026
- 8-K reportAug 13, 2026
- CLUSTER reportAug 5, 2026
- INST-CLUSTER reportJun 11, 2026
- 8-K reportJun 4, 2026
- PRESS-RELEASE reportJun 1, 2026
- 8-K reportMay 13, 2026
- PRESS-RELEASE reportMay 11, 2026
- DEFA14A reportApr 24, 2026